Cytonus Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cytonus Therapeutics's estimated annual revenue is currently $2.6M per year.(i)
  • Cytonus Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Cytonus Therapeutics has 17 Employees.(i)
  • Cytonus Therapeutics grew their employee count by 6% last year.

Cytonus Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Director OncologyReveal Email/Phone
3
Human Resources ManagerReveal Email/Phone
4
Scientist IIReveal Email/Phone
5
Molecular BiologistReveal Email/Phone
6
Research Associate IReveal Email/Phone
7
Research ScientistReveal Email/Phone
8
ControllerReveal Email/Phone
9
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Cytonus Therapeutics?

Cytonus Therapeutics Inc. is a San Diego-based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyteâ„¢ technologies are next-generation Biomolecular Delivery Transporterâ„¢ which have numerous medical applications across unmet therapeutic areas. Cargocytesâ„¢ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable allogeneic therapies.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.8M176%$21.4M
#2
$3.6M17N/AN/A
#3
$1.5M17N/AN/A
#4
$1.5M17N/AN/A
#5
$1.5M17N/AN/A